Is the price fair?
What VCYT's price assumes
Veracyte, Inc. trades at 41.0× earnings against 35.3× for the median Diagnostics & Research name, more expensive than its own group.
41.0
Trailing P/E · Diagnostics & Research median 35.3 · 1.16× the median: the market pays up for this one
- Price / sales
- 4.83
Price / sales · as of 2026-Q1
- Free cash flow yield
- 3.6%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +9.9%
Growth the price implies · The price pays for +9.9% free cash flow growth a year for a decade; the business has delivered +179% a year over the last three.
Details›
- Price / book2026-Q1
- 1.95
- Healthcare median P/E362 names
- 31.5
- Diagnostics & Research median P/E29 names
- 35.3
- Free cash flow, trailing twelve months
- $155M
- Market capitalisation
- $4.28B
- 3-year revenue growth
- +20%
- 3-year free cash flow growth
- +179%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #19 of 29 by Smart Score